Reengineering the pharmaceutical industry by crash-testing molecules

Drug Discovery Today

Volumn 10, Issue 17, 2005, Pages 1191-1200

  Swaan, Peter W ^a   Ekins, Sean ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b GeneGo bioinformatics software Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; SCORPION TOXIN BEKM 1; SCORPION TOXIN BMTX 3; SCORPION TOXIN CNERG 1; SCORPION VENOM; UNCLASSIFIED DRUG;

ALGORITHM; BIOINFORMATICS; BIOMEDICAL ENGINEERING; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; HUMAN; MATHEMATICAL COMPUTING; NONHUMAN; PREDICTION; REVIEW; SIMULATION; TOXICITY; TOXICOLOGY;

CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG INDUSTRY; FORECASTING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24944473469     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03557-9     Document Type: Review

References (120)

1. Bain W. Failure rates in drug discovery and development: will we ever get any better? Drug Discov World Fall 2004 9 18
2. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates Nat. Rev. Drug Discov. 3 2004 711 715
3. Pramik M.J. Molecular modeling ushers in the age of rational biotech drug design Genet. Eng News June 11 1989 38
4. Kaufmann W.J.I., Smarr L.L. Supercomputing and the Transformation of Science 1993 Scientific American Library
5. van de Waterbeemd H., Gifford E. ADMET in silico modelling towards prediction paradise? Nat Rev. Drug Discov. 2 2003 192 204
6. Beresford A.P. The emerging importance of predictive ADME simulation in drug discovery Drug Discov. Today 7 2002 109 116
7. Butina D. Predicting ADME properties in silico: methods and models Drug Discov. Today. 7 Suppl. 2002 S83 S88
8. Weintraub H.J.R. The race to integrate Curr. Drug Discov. Feb. 2003 23 27
9. Hopkins A.L., Groom C.R. The druggable genome Nat. Rev. Drug Discov. 1 2002 727 730
10. Greuel J.M. The R&D value conundrum Curr. Drug Discov. July 2002 37 42
11. Terstappen G.C., Reggiani A. In silico research in drug discovery Trends Pharmacol. Sci. 22 2001 23 26
12. Schneider M. A rational approach to maximize success rate in target discovery Arch. Pharm.(Weinheim) 337 2004 625 633
13. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico Drug Discov. Today 9 2004 276 285
14. Ekins S., Swaan P.W. Computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX Rev. Comp. Chem. 20 2004 333 415
15. Ekins S. Applying computational and in vitro approaches to lead selection Borchardt R.T. Pharmaceutical Profiling in Drug Discovery for Lead Selection 2004 AAPS Press 361 389
16. Yoon S. Computational identification of proteins for selectivity assays Proteins 59 2005 434 443
17. Whittaker P.A. What is the relevance of bioinformatics to pharmacology? Trends Pharmacol Sci. 24 2003 434 439
18. Kopec K.K. Target identification and validation in drug discovery: the role of proteomics Biochem. Pharmacol. 69 2005 1133 1139
19. Ekins S. Predicting drug-drug interactions in silico using pharmacophores: a paradigm for the next millennium Guner O.F. Pharmacophore Perception, Development and Use in Drug Design 2002 IUL 269 299
20. Ekins S. Progress in predicting human ADME parameters in silico J. Pharmacol. Toxicol. Methods 44 2000 251 272
21. Ekins S. Towards a new age of virtual ADME/TOX and multidimensional drug discovery J. Comput. Aided Mol. Des. 16 2002 381 401
22. Lyne P.D. Structure-based virtual screening: an overview Drug Discov. Today 7 2002 1047 1055
23. Sheridan R.P., Kearsley S.K. Why do we need so many chemical simialrity search methods? Drug Discov Today 7 2002 903 911
24. Bajorath J. Integration of virtula and high-throughput screening Nat. Rev. Drug Discov. 1 2002 882 894
25. Klebe G. Innovative lead discovery: from geometry to function and ligand design Curr. Drug Discov. July 2003 27 30
26. Engels M.F.M., Venkatarangan P. Smart screening: approaches to efficient HTS Curr. Opin. Drug Discov. Dev. 4 2001 275 283
27. Manly C.J. The impact of informatics and computational chemistry on synthesis and screening Drug Discov. Today 6 2001 1101 1110
28. Kennedy T. Managing the drug discovery / development interface Drug Discov. Today 2 1997 436 444
29. Thornton J.M. From structure to function: approaches and limitations Nat. Struct. Biol. 7 Suppl. 2000 991 994
30. Ma B. Multiple diverse ligands binding at a single protein site: A matter of pre-existing populations Protein Sci. 11 2002 184 197
31. Carlson H.A., McCammon J.A. Accomodating protein flexibility in computational drug design Mol. Pharmacol. 57 2000 213 218
32. Brinkworth R.I. Structural basis and prediction of substrate specificity in protein serine/threonine kinases Proc. Natl. Acad. Sci. U. S. A. 100 2003 74 79
33. Rockey W.M., Elcock A.H. Progress toward virtual screening for drug side effects Proteins 48 2002 664 671
34. Chen Y.Z., Ung C.Y. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach J. Mol. Graph. Model. 20 2001 199 218
35. Schneider G., Bohm H-J. Virtual screening and fast automated docking methods Drug Discov. Today 7 2002 64 70
36. Kubinyi H. Combinatorial and computational approaches in structure-based drug design Drug Discov. Dev. 1 1998 16 27
37. Shimada J. Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs Targets 1 2002 196 205
38. Egan W.J. Prediction of drug absorption using multivariate statistics J. Med. Chem. 43 2000 3867 3877
39. Cheng A. Computation of the physio-chemical properties and data mining of large molecular libraries J. Comput. Chem. 23 2002 172 183
40. Matter H. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa J. Med. Chem. 45 2002 2749 2769
41. Tikhonova I.G. CoMFA and homology-based models of the glycine binding site of N-methyl-d-aspartate receptor J. Med. Chem. 46 2003 1609 1616
42. Sharma V., Duffel M.W. Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling J. Med. Chem. 45 2002 5514 5522
43. Lyne P.D. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening J. Med. Chem. 47 2004 1962 1968
44. Lewell X.Q. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying priveleged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Comp. Sci. 38 1998 511 522
45. Xu J. A new approach to finding natural chemical structure classes J. Med. Chem. 45 2002 5311 5320
46. Patani G.A., LaVoie E.J. Bioisosterism: A rational approach in drug design Chem. Rev. 96 1996 3147 3176
47. Ertl P. Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like properties J. Chem. Inf. Comp. Sci. 43 2003 374 380
48. Andrews P.R. Functional group contributions to drug-receptor interactions J. Med. Chem. 27 1984 1648 1657
49. Blundell T.L. High-throughput crystallography for lead discovery in drug design Nat. Rev. Drug Discov. 1 2002 45 54
50. Mochalkin, I. et al (2003) Structure-Based Drug Discovery in Informatics Environments, Accelrys
51. Adams P.D. Recent developments in the PHENIX software for automated crystallographic structure determination J. Synchrotron Radiat. 11 2004 53 55
52. Lipinski C.A. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
53. Navia M.A., Chaturvedi P.R. Design principles for orally bioavailable drugs Drug Discov. Today 1 1996 179 189
54. Veber D.F. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623
55. Blake J. Examination of the computed molecular properties of compounds selected for clinical development Biotechniques (June Suppl.) 2003 16 20
56. Oprea T.I. Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 41 2001 1308 1315
57. Walters W.P., Murcko M.A. Prediction of 'drug-likeness' Adv. Drug Deliv. Rev. 54 2002 255 271
58. Wenlock M.C. A comparison of physicochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250 1256
59. Vieth M. Characteristic physical properties and structural fragments of marketed oral drugs J. Med. Chem. 47 2004 224 232
60. US Food and Drug Administration (2004) Innovation stagnation: challenge and opportunity on the critical path to new medicinal products (http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
61. Boobis A. In silico prediction of ADME and pharmacokinetics: Report of an expert meeting organised by COST B15 Eur. J. Pharm. Sci. 17 2002 183 193
62. Greene N. Computer systems for the prediction of toxicity: an update Adv. Drug Deliv. Rev. 54 2002 417 431
63. King L.A. Ferguson's principle and the prediction of fatal drug levels in blood Hum. Toxicol. 4 1985 273 278
64. Tichy M. QSAR approach to estimation of the distribution of xenobiotics and the target organ in the body Drug Metabol. Drug Interact. 9 1991 191 200
65. Mekenyan O. Bronchospasmolytic activity and toxicity modeling of theophylline derivatives by a microcomputer based method Arzneim. Forsch./Drug Res. 43 1993 1341 1350
66. Blower P. On combining recursive partitioning and simulated annealing to detect groups of biologically active compounds J. Chem. Inf. Comput. Sci. 42 2002 393 404
67. Young S.S. Mixture deconvolution and analysis of Ames mutagenicity data Chemomet. Intell. Lab. Syst. 60 2002 5 11
68. Espinosa G. An integrated SOM-fuzzy ARTMAP neural system for the evaluation of toxicity J. Chem. Inf. Comput. Sci. 42 2002 343 359
69. Giampaolo C. Predicting chemically induced duodenal ulcer and adrenal necrosis with classification trees Proc. Natl. Acad. Sci. U. S. A. 88 1991 6298 6302
70. Contrera J.F. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices Regul. Toxicol. Pharmacol. 38 2003 243 259
71. Duart M.J. Use of molecular topology for the prediction of physico-chemical, pharmacokinetic and toxicological properties of a group of antihistaminic drugs Int. J. Pharmaceut. 246 2002 111 119
72. Richard A.M., Williams C.R. Distributed structure-searchable toxicity (DSSTox) public database network: a proposal Mutat. Res. 499 2002 27 52
73. Waters M. Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base EHP Toxicogenomics 111 1T 2003 15 28
74. Flower D. Towards in silico prediction of immunogenic epitopes Trends Immunol. 24 2003 667 674
75. Korolkova Y.V. New binding site on common molecular scaffold provides HERG channel specificity of scorpion toxin BeKm-1 J. Biol. Chem. 277 2002 43104 43109
76. Torres A. Solution structure of CnErg1 (Ergtoxin), a HERG specific scorpion toxin FEBS Lett. 539 2003 138 142
77. Huys I. BmTx3, a scorpion toxin with two putative functional faces separately active on A-type K+ and HERG currents Biochem. J. 378 2004 745 752
78. Ekins S. Three-dimensional quantitative structure activity relationship for the inhibition of the hERG (human ether-a-gogo related gene) potassium channel J. Pharmacol. Exp. Therapeut. 301 2002 427 434
79. Cavalli A. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers J. Med. Chem. 45 2002 3844 3853
80. Pevzner P.A. Computational Molecular Biology 2000 MIT Press
81. Bower J.M., Bolouri H. Computational Modeling of Genetic and Biochemical Network 2001 MIT Press
82. Barabasi A-L., Oltvai Z.N. Network biology: understanding the cell's functional organization Nat. Rev. Genet. 5 2004 101 113
83. Giot L. A protein interaction map of Drosophila melanogaster Science 302 2003 1727 1736
84. Palsson B.O. What lies beyond bioinformatics? Nat Biotechnol. 15 1997 3 4
85. Kitano H. Computational systems biology Nature 420 2002 206 210
86. Christopher R. Data-driven computer simulation of human cancer cell Ann. N. Y. Acad. Sci. 1020 2004 132 153
87. Defranoux N.A. In silico modeling and simulation of bone biology: a proposal J. Bone Miner. Res. 20 2005 1079 1084
88. Plavec I. Method for analyzing signaling networks in complex cellular systems Proc. Natl. Acad. Sci. U. S. A. 101 2004 1223 1228
89. Ekins S. A Novel Method for Visualizing Nuclear Hormone Receptor Networks Relevant to Drug Metabolism Drug Metab. Dispos. 33 2005 474 481
90. Nikolsky Y. A novel method for generation of signature networks as biomarkers from complex high throughput data Toxicol. Lett. 158 2005 20 29
91. Siripurapu V. DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways J. Mol. Biol. 346 2005 83 89
92. Ekins S. Techniques: Application of Systems Biology to Absorption, Distribution, Metabolism, Excretion and Toxicity Trends Pharmacol. Sci. 26 2005 202 209
93. Ekins S. Systems biology: applications in drug discovery Gad S. Drug Discovery Handbook 2003 Wiley 123 183
94. Wanchana S. Quantitative structure/property relationship analysis on aqueous solubility using genetic algorithm-combined partial least squares method Pharmazie 57 2002 127 129
95. Young S.S. So many targets, so many compounds, but so few resources Curr. Drug Disc December 2002 17 22
96. Dearden J.C. Quantitative structure-property relationships for prediction of boiling point, vapor pressure, and melting point Environ. Toxicol. Chem. 22 2003 1696 1709
97. Dearden J.C. The QSAR prediction of melting point, a property of environmental relevance Sci. Total Environ 1999 109 110 59-68
98. Chen Y. the application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms J. Control. Release 59 1999 33 41
99. Mattioni B.E., Jurs P.C. Prediction of glass transition temperatures from monomer and repeat unit structure using computational neural networks J. Chem. Inf. Comput. Sci. 42 2002 232 240
100. Bourquin J. Advantages of artificial neural networks (ANNs) as alternative modelling technique for data sets showing non-linear relationships using data from a galenical study on a solid dosage form Eur. J. Pharm. Sci. 7 1998 5 16
101. Ebube N.K. Preformulation studies and characterization of the physicochemical properties of amorphous polymers using artificial neural networks Int. J. Pharmaceut. 196 2000 27 35
102. Van den Mooter G. Stability prediction of amorphous benzodiazepines by calculation of the mean relaxation time constant using the Williams-Watts decay function Eur. J. Pharm. Biopharm. 48 1999 43 48
103. Almarsson O., Gardner C.R. Novel approaches to issues of developability Curr. Drug Discov Jan 2003 21 26
104. Morissette S.L. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization Proc. Natl. Acad. Sci. U. S. A. 100 2003 2180 2184
105. Tarvainen M. Predicting the plasticization efficiency from the three-dimensional molecular structure of a polymer plasticizer Pharm. Res. 18 2001 1760 1766
106. Hirono S. Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: oral bioavailability Biol. Pharm. Bull. 17 1994 306 309
107. Hirono S. Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least squares: volume of distribution Biol. Pharm. Bull. 17 1994 686 690
108. Gobburu J.V.S., Shelver W.H. Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks J. Pharm. Sci. 84 1995 862 865
109. Mahmoud I., Miller R. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis Int. J. Clin. Pharmacol. Therapeut. 37 1999 439 445
110. Michelson S. Assessing the impact of predictive biosimulation on drug discovery and development J. Bioinform. Comput. Biol. 1 2003 169 177
111. Kansal A.R. Modeling approaches to type 2 diabetes Diabetes Technol. Ther. 6 2004 39 47
112. Musante C.J. Small- and large-scale biosimulation applied to drug discovery and development Drug Discov. Today. 7 Suppl. 20 2002 S192 S196
113. Eddy D.M., Schlessinger L. Validation of the archimedes diabetes model Diabetes Care 26 2003 3102 3110
114. Eddy D.M., Schlessinger L. Archimedes: a trial-validated model of diabetes Diabetes Care 26 2003 3093 3101
115. Bain W. Failure rates in drug discovery and development: will we ever get any better? Drug Discov World 2003 9 18
116. Natarajan R. A computer program for sample size and power calculations in the design of multi-arm and factorial clinical trials with survival time endpoints Comput. Meth. Prog. Biomed. 49 1996 137 147
117. Toscani M.R., Resnick G. Postmarketing studies: methods for implemetation and potential use of data Drug Inf. J. 26 1992 261 265
118. Stallard N., Thall P.F. Decision-theoretic designs for pre-Phase II screening trials in oncology Biometrics 57 2001 1089 1095
119. Kuhlmann J., Muck W. Clinical-Pharmacological strategies to assess drug interaction potential during drug development Drug Saf. 24 2001 715 725
120. Pieraccioli D. Patenting the pharmacophore Curr. Drug Discov Oct 2002 40 43